Detailed Information on Publication Record
1994
Cisplatina a karboplatina při léčbě maligních lymfomů a mnohočetného myelomu
ADAM, Zdeněk, Jiří MAYER and Roman HÁJEKBasic information
Original name
Cisplatina a karboplatina při léčbě maligních lymfomů a mnohočetného myelomu
Name (in English)
Cisplatin and carboplatin in the treatment of malignant lymphoma and multiple myeloma
Authors
ADAM, Zdeněk (203 Czech Republic), Jiří MAYER (203 Czech Republic, guarantor) and Roman HÁJEK (203 Czech Republic)
Edition
Vnitřní lékařství, Praha, Česk lékařská společnost J. Ev. Purkyně, 1994, 0042-773X
Other information
Language
Czech
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
Organization unit
Faculty of Medicine
Keywords (in Czech)
cisplatina; lymfom; mnohočetný myelom
Keywords in English
cisplatin;carboplatin;lymphoma; multiple myeloma
Tags
Změněno: 24/6/2009 10:39, Mgr. Anna Potáčová, Ph.D.
V originále
Toto review shrnuje poznatky o užívání cisplatiny přo léčbě mnohočetného myelomu a zhoubných lymfomů.
In English
Experiences with cisplatin and carboplatin are summarized in this paper. The treatment response to monotherapy with cisplatin or carboplatin was proved in non-Hodgkin's lymphomas. This is necessary condition for the application of the drug in polychemotherapy. Cisplatin and carboplatin based combinations are not used as an initial therapy. The indications for these two drugs are primary resistant malignant lymphoma and multiple myeloma, or relapses of these diseases not responding to conventional therapy. Cisplatin based combination therapy can in these indications prolong the survival in 30-40% of patients. The role of carboplatin in malignant lymphoma is not clear yet and is under investigation. The effective antiemetic therapy (ondansetron, granisetron) miligated the fear of vomiting and therefore these combinations are used in resistant malignant lymphoproliferative diseases more then some years ago. In the tables are shown the chemotherapeutic combinations used in non-Hodgkin's lymphomas, Hodgkin disease and multiple myeloma.